A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration - Boyer, David S.; Heier, Jeffrey S.; Brown, David M.; Francom, Steven F.; Ianchulev, Tsontcho; Rubio, Roman G. (Ophthalmology (Rochester, Minn.), 2009)
Keywords: Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Biological and medical sciences; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Female; Follow-Up Studies; Humans; Injections; Macular Degeneration - complications; Macular Degeneration - drug therapy; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Ranibizumab; Retinopathies; Retreatment; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - drug effects; Vitreous Body; Human; Retinopathy; Phase; Toxicity; Monoclonal antibody; Immunomodulator; Eye disease; Vascular endothelium growth factor; Ranibizumab; Age related macular degeneration; Neovascularization; Ophthalmology; Safety; Antiangiogenic agent